A Randomised, Double-Blind, Study Comparing ARIMIDEX With NOLVADEX as Neo-Adjuvant and Adjuvant Treatment in Post-Menopausal Women With Large Operable (T2 (=3cm), T3, N0-2, M0) or Potentially-Operable, Locally Advanced (T4b, N0-2, M0), ER+ and/or PR+ Breast Cancer

Phase 3

• Conditions: Breast Cancer

• Registration Number: JPRN-jRCT2080220266
• Lead Sponsor: AstraZeneca

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2006-06-30
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Sex: Female
• Target Recruitment: Not specified

Inclusion Criteria

Ages Eligible for Study: 60 Years and above, Genders Eligible for Study: Female
Criteria
Inclusion Criteria:
- Operable or potentially operable breast cancer
- Invasive breast cancer proven to be hormone-sensitive (ER+/PR+)
- Patients who might benefit from endocrine treatment prior to surgery
- Postmenopausal
- Signed written informed consent

Exclusion Criteria

- Inoperable breast cancer
- Patient unwilling to undergo surgery
- Any reason why the patient may not be able to conform to study requirements
- Any previous treatment for breast cancer
- Previous Tamoxifen use as a part of breast cancer prevention trials
- Not willing to stop taking drugs that affect sex-hormones such as HRT
- Previous history of breast cancer
- Previous history of invasive malignancy within the last 10 years
- Any other severe disease that may prevent surgery, place the patient at risk, or influence the study results
- Treatment with an experimental drug within the last 3 months
- Risk of transmitting HIV, Hepatitis B or C

Study & Design

• Study Type: Interventional
• Study Design: Not specified